

20 February 2014  
 EMA/CHMP/BWP/85290/2012  
 Committee for Medicinal Products for Human Use (CHMP)

## Guideline on the declaration of the quantitative composition / potency labelling of biological medicinal products that contain modified proteins as active substance

Draft agreed by Biologics Working Party	February 2013
Agreed by Blood Products Working Party	February 2013
Adopted by Committee for Medicinal Products for Human Use for release for consultation	March 2013
Start of public consultation	March 2013
End of consultation (deadline for comments)	1 October 2013
Agreed by Biologics Working Party	January 2014
Agreed by Blood Products Working Party	January 2014
Adopted by Committee for Medicinal Products for Human Use	20 February 2014
Date for coming into effect	1 September 2014 <sup>1</sup>

<b>Keywords</b>	<b><i>Declaration, quantitative composition, product labelling, biopharmaceuticals, modified proteins, potency, unit, clinical practice, product information</i></b>
-----------------	--

<sup>1</sup> First day of the 7th month.



# **Guideline on the declaration of the quantitative composition / potency labelling of biological medicinal products that contain modified proteins as active substance**

## **Table of contents**

<b>Executive summary .....</b>	<b>3</b>
<b>1. Introduction (background).....</b>	<b>3</b>
<b>2. Scope.....</b>	<b>4</b>
<b>3. Legal basis .....</b>	<b>4</b>
<b>4. Discussion .....</b>	<b>5</b>
4.1. Strategies for declaration of the quantitative composition / potency labelling for biological medicinal products that contain modified proteins as active substance.....	5
4.2. Specific considerations for SmPC /Labelling .....	7
<b>References .....</b>	<b>8</b>

## **Executive summary**

This guideline outlines the approaches to be followed for declaring the quantitative composition / potency labelling of medicinal products that include modified proteins as their active substance, taking into account the product class and the clinically established declared value (e.g. international unit, mass unit) for the non-modified product, the method of assay (biological or physico-chemical), and relevance of the potency assay (i.e. correlated with clinical efficacy). For product labelling, it is considered important that the chosen unitage will not be confusing in clinical practice. The product information for healthcare professionals and patients must clearly differentiate the modified product from the non-modified product. This document also discusses the use of the activity unit to define a quality attribute during product manufacture and control.

## **1. Introduction (background)**

There is an increasing interest of Industry to develop new biopharmaceuticals based on modifications of established protein therapeutics with the aim to modulate the *in vivo* properties of these products. The introduced structural modifications could be a removal or replacement of one, or a few, amino acids in the molecule, which is achieved by modification of the gene, by chemical modifications such as conjugation to a carrier molecule applied after biosynthesis of the protein, or by engineering of post-translational modifications such as glycoengineering. Such intentionally modified products include, for example, pegylated forms of growth hormones, pegylated erythropoietins, and pegylated coagulation factors, as well as human serum albumin or Fc receptor portion as fusion protein for interferon alpha and coagulation factors. PEGylated products that have already been authorised include PegFilgrastim (ref1), PegInterferon-alpha (ref2), Methoxy polyethylene glycol-epoetin beta (ref3). Darbepoetin alfa could be considered as an example of a glycoengineered product (ref4).

For complex biological medicines that cannot be fully characterised by physicochemical means, the established concept is to assign potency, in units of biological activity, based on the use of an international standard for biological activity. The units of biological activity are mostly traced back to an internationally adopted reference preparation (International Standard, IS). The quantitative composition and dosing recommendation of biological medicinal products for which an IS exists is expressed in international units (IU).

Medicinal products containing modified proteins as their active substance are likely to be used in the same clinical context and indications as their parent compounds. However, since modified products are intentionally different from their parent compounds, they cannot always be standardized in a similar way against the International Standard developed for the parent compound. There is a risk that modified products could be considered as equivalent to the "parent" products in particular when they are intended for the same therapeutic indication and are given the same unitage as their parent counterpart. Therefore other approaches for potency assignments may be needed for modified products to assure proper usage of those products in clinical practice.

ICH Q6B (ref5) states: "The results of biological assays should be expressed in units of activity calibrated against an international or national reference standard, when available and appropriate for the assay utilised. Where no such reference standard exists, a characterised in-house reference material should be established and assay results of production lots reported as in-house units."

According to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards (ref 6), the behaviour of the reference standard

should resemble as closely as possible the behaviour of the test samples in the assay used to test them. The general principle is that of "like versus like".

These documents provide guidance about setting specifications, including potency and quantity, of biological medicinal products and criteria for reference standards for the purpose of standardisation and control. Hence, the principles outlined in these documents only refer to standardisation and control but do not necessarily serve the purpose for declaring the content of the drug product and dosing recommendation. Different strategies as regards the unitage can be followed.

Modified products may have similar responses as their "parent" compounds in in vitro biological assays for potency assignment, where the structural modification(s) do not impact the relation between the tested molecule and its in vitro activity. Nevertheless, there may be a different correlation between units assigned in vitro and clinical response for the modified and the parent compound.

Companies define their own strategy for declaration of the quantitative composition / potency labelling and product information. Such strategies have to be scientifically valid and it is desirable to have a consistent approach within a product class. Therefore, thorough consideration should be given to the declaration of the quantitative composition / potency labelling of modified products.

EMA guidance documents related to aspects of potency labelling and declaration of composition for insulin analogues and pegylated proteins have been published (ref 7, 8). It should be noted that the current document does not replace these guidance documents but rather should be read in conjunction.

This document provides guidance about the various strategies that can be followed for the declaration of the quantitative composition / potency labelling of medicinal products that contain modified proteins as their active substance.

## **2. Scope**

This guideline will apply to medicinal products that contain modified proteins as their active substance. In this respect, modified proteins refer to proteins that are intentionally modified (e.g. conjugated, pegylated, post-translationally modified or amino acid modifications), so that they are structurally different from their "parent" non-modified proteins and as a result behave differently in vivo.

However, the principles adopted and explained in this guideline may also be applicable to proteins which are modified for other reasons than changing their in vivo behaviour, (e.g. to improve production of the protein), and thus are expected to have the same in vivo behaviour as the parent protein.

## **3. Legal basis**

This guideline has to be read in conjunction with the introduction and general principles (4) and Annex I to Directive 2001/83/EC as amended.

## 4. Discussion

### 4.1. Strategies for declaration of the quantitative composition / potency labelling for biological medicinal products that contain modified proteins as active substance

Biological medicinal products are labelled in units of biological activity (IU or units) or mass unit. Where mass units are used for the declaration of content, the specific activity (IU/mg or u/mg) or the relative potency (relative to an in-house standard) is often specified as an additional quality attribute as part of the quality control strategy. The strategy to apply for modified proteins should therefore address two separate but evidently related issues:

A- the unit to declare (i.e. label) the content of a preparation

B- the activity unit to define a quality attribute during manufacture and control.

#### **A: the unit to declare (i.e. label) the content of a preparation**

The strategy for declaring the quantitative composition that would be acceptable for a product containing a modified protein will likely have to be considered on a case-by-case basis. Therapeutic proteins constitute a large number of products applied in a wide range of therapeutic areas and as such it may be difficult to follow a "one fits all approach".

Three different situations are envisaged:

- Product labelling in mass units
- Product labelling in "in-house units", i.e. the unitage is product specific
- Product labelling in International Units

#### Product labelling in mass units

Labelling in product specific mass units will be appropriate in situations:

- Where the quantitative composition of the parent compound is expressed on a protein content basis (e.g. in the case where physicochemical tests alone are used to quantitate the biological activity)
- Where the quantitative composition of the parent compound is declared on the basis of units of biological activity but an equivalent declaration for the modified product is not desirable (e.g. to prevent dosing errors as explained below). A declaration on a protein content basis is preferred, provided that the formulation and filling of the product is based on mass and all dosing recommendations (derived from clinical trials) are based on the protein content.

Where the active protein is conjugated to a carrier molecule the labelled mass should refer to the active protein part of the conjugate. The SmPC should explain the nature of the conjugate and also state the mass of the entire conjugate. Further guidance is given in the CPMP Guidance on the description of composition of pegylated (conjugated) proteins in the SPC (ref8).

### Product labelling in product specific “in-house units”

Labelling in product specific “in-house units” will be appropriate in situations:

- Where the quantitative composition of the parent compound is expressed in units of biological activity,

AND

- Where there is no International Standard for biological activity available or where the International Standard for biological activity is not appropriate for the modified product e.g. if statistically invalid estimates relative to the IS are obtained (ref9), or the biological activity measured relative to the IS does not correlate to the clinical response, or where the biological activity measured in the bioassay is not directly relevant or related to the mode of action in the clinical situation.

In such cases, the establishment of a product specific activity unit is common and the assay results are reported as “in-house units” in accordance with ICH guideline Q6B (ref5). Accordingly, the product should then be labelled in “in-house units”.

Where an IS is available and shown suitable for the assay utilised for the modified product, the assay results could in principle be reported in International Units. However, in most cases the product is still labelled in product specific “in-house units” to prevent dosing errors.

### Product labelling in International Units

Whilst in most cases product labelling will be in mass units or “in-house units”, there may be exceptional cases, i.e. coagulation factors used in replacement therapy, where it is desirable and justified to use product labelling in International Units. For these products, clinical efficacy is monitored in patients by measuring coagulation factor activity in post-infusion plasma samples in IU. For coagulation factors used in replacement therapy it has become common clinical practice to dose in IU. For modified versions of these proteins the potency assay established for each product in this class should be based on thorough characterisation of the modified product with respect to potency assays including the effect of different methods / reagents on measured potency in vitro and on data from in vivo clinical studies. A label claim could then be in IU, provided that the validity of the assay relative to the International Standard (linearity, parallelism) is established.

### **B: the activity unit to define a quality attribute during manufacture and control**

For products where the content is declared in mass units as explained in section A above, there may still be a need to measure and assign biological activity as a quality attribute to appropriately control the quality/characteristics of the product, e.g. in the determination of specific activity.

As outlined in guideline ICH Q6B, for complex biological molecules, the physicochemical information may be extensive but unable to confirm all structural aspects relevant for biological activity such as the higher-order structure. In such cases, a biological assay should complete the testing of the drug substance and drug product wherever appropriate. Where an IS is available for the parent compound and shown suitable, assay results could be expressed in IU. Where an IS based on the modified protein is available and applicable, a “like vs like” approach would normally be applied. Where no IS exists, a characterised in-house reference material should be established and assay results of production lots reported as in-house units.

Nevertheless, where sufficient physicochemical information about the drug substance, including higher-order structure, can be thoroughly established by physicochemical methods, and relevant correlation to

biologic activity has been demonstrated, a bioassay for the purpose of routine control at Drug Substance and/or Drug Product level, will not be needed.

In case of conjugated proteins consideration should be given to a situation where the use of a bioassay on the conjugate (Drug Substance, Drug Product) does not provide a valid potency calibration and thus an appropriate assay for the conjugate does not exist. In such cases physico-chemical characterisation of the conjugate should in any case complement the bioactivity specified for the protein before conjugation. As part of the quality control strategy, the substance before conjugation should be tested using the same assay as commonly applied for the parent compound and the unitage will be IU if an IS exists. Appropriate limits for bioactivity should be set.

#### *4.2. Specific considerations for SmPC /Labelling*

Quantitative composition of the modified product may be expressed in mass or "in-house units" or International Units as described above. The product information should explain that "in-house units" are product specific.

As for any medicinal product, the relationship between the quantitative composition of the modified product and clinically relevant parameters (e.g. pharmacokinetics and posology) will be established in clinical studies. Since the modified product is typically used in the same clinical indication as the non-modified product, it is important that the product information contains clear information for healthcare professionals and patients to differentiate the modified product from the non-modified product and avoid confusion in clinical use. The SmPC and package leaflet for the product containing the modified protein include an appropriate explanation of the relationship between the modified protein and the parent protein in terms of in vivo activity and pharmacokinetics and the consequences for posology. Useful information may also be found in the SSC/ISTH recommendations on the potency labelling of factor VIII and factor FIX concentrates (ref10).

Particularly, further information and guidance could be given in the following sections, as appropriate:

- Section 2 "Qualitative and quantitative composition"
- Section 4.2 Posology and Methods of Administration
- Section 5.1 Pharmacodynamic properties
- Section 5.2 Pharmacokinetic properties

Further guidance and examples are available in regulatory documents, such as:

- SmPC guideline [ref11]
- Core SmPCs for human plasma and recombinant coagulation factors [ref12,13]
- QRD template
- CHMP Guideline on potency labelling for Insulin analogue containing products with particular reference to the use of "International Units" or "Units" [ref7]
- CPMP Guidance on the description of composition of pegylated (conjugated) proteins in the SPC [ref8]
- European Public Assessment Reports (EPARS) of licensed products

## References

1. EPAR Neulasta (pegfilgrastim). [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Scientific\\_Discussion/human/000420/WC500025941.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000420/WC500025941.pdf)
2. EPAR Pegasys (peginterferon alfa-2a). [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Scientific\\_Discussion/human/000395/WC500039192.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000395/WC500039192.pdf)
3. EPAR Mircera (methoxy polyethylene glycol-epoetin beta). [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Scientific\\_Discussion/human/000739/WC500033669.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000739/WC500033669.pdf)
4. EPAR Aranesp (darbepoetin alfa). [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Summary\\_for\\_the\\_public/human/000332/WC500026141.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000332/WC500026141.pdf)
5. ICH Q6B Test procedures and acceptance criteria for biotechnological/biological products (CPMP/ICH/365/96); [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500002824](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500002824)
6. WHO Technical Report Series, No. 932, 2006, Annex 2. Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004); [http://www.who.int/entity/immunization\\_standards/vaccine\\_reference\\_preparations/TRS93\\_2Annex%202\\_Inter%20\\_biol%20ef%20standards%20rev2004.pdf](http://www.who.int/entity/immunization_standards/vaccine_reference_preparations/TRS93_2Annex%202_Inter%20_biol%20ef%20standards%20rev2004.pdf)
7. CHMP Guideline on potency labelling for Insulin analogue containing products with particular reference to the use of "International Units" or "Units", EMEA/CHMP/BWP/124446/2005; [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500003612](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003612)
8. CPMP Guidance on the description of composition of pegylated (conjugated) proteins in the SPC, EMEA/CPMP/BWP/3068/03; [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500003661](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003661)
9. European Pharmacopoeia Chapter 5.3. Statistical analysis of results of biological assays and tests
10. Hubbard AR, Dodt J, Lee T, Mertens K, Seitz R, Srivastava A, Weinstein M, on behalf of the Factor VIII and Factor IX Subcommittee of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Recommendations on the potency labelling of factor VIII and factor IX concentrates. *J Thromb Haemost*. 2013; 11:988-9. doi: 10.1111/jth.12167.
11. Guideline on Summary of Product Characteristics (SmPC), rev. 2. EC Notice to Applicants. September 2009. [http://ec.europa.eu/health/files/eudralex/vol-2/c/smfp\\_guideline\\_rev2\\_en.pdf](http://ec.europa.eu/health/files/eudralex/vol-2/c/smfp_guideline_rev2_en.pdf)
12. CHMP Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products, EMA/CHMP/BPWP/1619/1999 rev. 1; [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500128995](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500128995)
13. CHMP Guideline on core SmPC for human plasma derived and recombinant coagulation factor IX products, EMA/CHMP/BPWP/1625/1999 rev. 1; [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500128994](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500128994)

